Literature DB >> 26823212

What are the characteristics of asthma patients with elevated serum IgG4 levels?

T Flament1, S Marchand-Adam2, P Gatault3, C Dupin1, P Diot2, L Guilleminault4.   

Abstract

INTRODUCTION: IgG4 has recently been a subject of great interest in human pathology. No data are available about the characteristics of asthma patients with elevated IgG4 levels. POPULATION AND METHODS: An observational study was conducted from January 2006 to March 2015 in a difficult-to-treat population of asthma patients. Twenty-six difficult-to-treat asthma patients with elevated serum IgG4 levels (IgG4/IgG ratio up to 10%) were compared with a control population of 98 difficult-to-treat asthma patients with normal serum IgG4. Blood eosinophilia, total IgE and FeNO were compared between groups to better characterize asthma patients with elevated serum IgG4 levels.
RESULTS: Median IgG4 concentrations were 1.72 g/l [1.19-2.36] and 0.22 g/l [0.10-0.49] in the elevated IgG4 group and normal Ig4 group, respectively. Median blood eosinophilia was more than three times higher in patients with elevated serum IgG4 levels than in controls (0.75 10(9)/L [IQR 0.54-1.78] vs 0.22 10(9)/L [IQR 0.09-0.54] respectively, p < 0.0001). Total IgE was twice as high (264.5 kUI/l [IQR 166.3-779] vs 126 kUI/l [IQR 26-350] respectively; p < 0.05) and FeNO was nearly twice as high (61 [IQR 41-111] ppb vs 35 [IQR 23-51] ppb, p < 0.001). Allergic broncho-pulmonary aspergillosis (ABPA) and eosinophilic granulomatosis with polyangiitis (EGPA) were observed in the asthma patients with elevated serum IgG4. Ten patients had unexplained increased blood eosinophilia.
CONCLUSION: Asthma patients with elevated IgG4 levels have significantly higher blood eosinophilia, total IgE and FeNO. ABPA and EGPA are observed in patients with elevated serum IgG4.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allergic broncho-pulmonary aspergillosis; Asthma; Eosinophilic granulomatosis with polyangiitis; IgG4

Mesh:

Substances:

Year:  2016        PMID: 26823212     DOI: 10.1016/j.rmed.2016.01.014

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  A Case of Eosinophilic Granulomatosis with Polyangiitis Complicated with A IgG4 Related Disease Like Symptoms.

Authors:  Suguru Sato; Julia Morimoto; Yasuharu Oguchi; Takashi Umeda; Takaya Kawamata; Mami Rikimaru; Tatsuhiko Koizumi; Ryuichi Togawa; Yasuhito Suzuki; Yuki Sato; Manabu Uematsu; Hiroyuki Minemura; Takefumi Nikaido; Atsuro Fukuhara; Junpei Saito; Kenya Kanazawa; Yoshinori Tanino; Mitsuru Munakata; Yoko Shibata
Journal:  Case Reports Immunol       Date:  2018-11-04

2.  Host and parasite responses in human diffuse cutaneous leishmaniasis caused by L. amazonensis.

Authors:  Stephen M Christensen; Ashton T Belew; Najib M El-Sayed; Wagner L Tafuri; Fernando T Silveira; David M Mosser
Journal:  PLoS Negl Trop Dis       Date:  2019-03-07

3.  Severe asthma as the initial clinical manifestation of IgG4-related disease: a retrospective clinical study.

Authors:  Xiangning Liu; Chi Shao; Chen Yu; Hui Huang; Ruili Pan; Kai Xu; Xin Zhang; Zuojun Xu
Journal:  BMC Pulm Med       Date:  2022-04-12       Impact factor: 3.317

4.  Clinical and immunological characteristics of Aspergillus fumigatus-sensitized asthma and allergic bronchopulmonary aspergillosis.

Authors:  Hao Chen; Xinyu Zhang; Li Zhu; Nairui An; Qing Jiang; Yaqi Yang; Dongxia Ma; Lin Yang; Rongfei Zhu
Journal:  Front Immunol       Date:  2022-08-02       Impact factor: 8.786

Review 5.  Allergic Aspects of IgG4-Related Disease: Implications for Pathogenesis and Therapy.

Authors:  Despina Michailidou; Daniella Muallem Schwartz; Tomas Mustelin; Grant C Hughes
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

Review 6.  IgG4-related disease with tracheobronchial miliary nodules and asthma: a case report and review of the literature.

Authors:  Xiuling Wang; Jun Wan; Ling Zhao; Jiping Da; Bin Cao; Zhenguo Zhai
Journal:  BMC Pulm Med       Date:  2019-10-30       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.